Slope initially began as a blog, so this is where most of the website’s content resides. Here we have tens of thousands of posts dating back over a decade. These are listed in reverse chronological order. Click on any category icon below to see posts tagged with that particular subject, or click on a word in the category cloud on the right side of the screen for more specific choices.
Tesla’s (TSLA) meteoric rise from June this year has sent it to all-time highs, as shown on the following monthly chart…and has resulted in a 119.67% gain since then, as shown on the next graph. It’s been heavily favoured above the FAANGs.
Based on the trajectory of the Andrew’s Pitchfork formation, its next major resistance lies around the 450 level.
The Balance of Power lies firmly with buyers and is approaching an all-time high. Watch for that to continue on this longer-term timeframe to support a further rally.
(Note from Tim; NFTRH was kind enough to post this, and I accidentally published a snippet of the article early today; here, in all its glory, is the complete article):
The Continuum (the systematic downtrend in long-term Treasury yields) has for decades given the Fed the green light on inflation. Sometimes it runs hot (as per the red arrows) and sometimes it runs cold. One year ago people were confused about why a declining stock market was not influencing Fed chief Powell to reverse his relatively hawkish tone.
These four stocks are moving on news and gaining technical momentum.
Axsome Therapeutics, Inc. (AXSM) jumped $8.60 to $89.57 on 2.6 million shares Wednesday, more than double its average volume. On Monday the biotech company said its experimental treatment for depression met the primary endpoint in a Phase 3 clinical trial. The move popped the stock through the top of an already steep channel rising from the $20 level just two months ago. Watch for $106 next.
Bed Bath & Beyond Inc. (BBBY) gained 84 cents to $17.72 on 10.5 million shares Wednesday. The move followed news of a restructuring in which six senior leaders are leaving the specialty retailer. The stock has been stair-stepping up its rising channel since its mid-August low at $7.31, and the channel top now points to a target of $20-$20.50.